Gene expression profiling of 49 human tumor xenografts from in vitro culture through multiple in vivo passages - strategies for data mining in support of therapeutic studies
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Development of cancer therapeutics partially depends upon selection of appropriate animal models. Therefore, improvements to model selection are beneficial. RESULTS: Forty-nine human tumor xenografts at in vivo passages 1, 4 and 10 were subjected to cDNA microarray analysis yielding a dataset of 823 Affymetrix HG-U133 Plus 2.0 arrays. To illustrate mining strategies supporting therapeutic studies, transcript expression was determined: 1) relative to other models, 2) with successive in vivo passage, and 3) during the in vitro to in vivo transition. Ranking models according to relative transcript expression in vivo has the potential to improve initial model selection. For example, combining p53 tumor expression data with mutational status could guide selection of tumors for therapeutic studies of agents where p53 status purportedly affects efficacy (e.g., MK-1775). The utility of monitoring changes in gene expression with extended in vivo tumor passages was illustrated by focused studies of drug resistance mediators and receptor tyrosine kinases. Noteworthy observations included a significant decline in HCT-15 colon xenograft ABCB1 transporter expression and increased expression of the kinase KIT in A549 with serial passage. These trends predict sensitivity to agents such as paclitaxel (ABCB1 substrate) and imatinib (c-KIT inhibitor) would be altered with extended passage. Given that gene expression results indicated some models undergo profound changes with in vivo passage, a general metric of stability was generated so models could be ranked accordingly. Lastly, changes occurring during transition from in vitro to in vivo growth may have important consequences for therapeutic studies since targets identified in vitro could be over- or under-represented when tumor cells adapt to in vivo growth. A comprehensive list of mouse transcripts capable of cross-hybridizing with human probe sets on the HG-U133 Plus 2.0 array was generated. Removal of the murine artifacts followed by pairwise analysis of in vitro cells with respective passage 1 xenografts and GO analysis illustrates the complex interplay that each model has with the host microenvironment. CONCLUSIONS: This study provides strategies to aid selection of xenograft models for therapeutic studies. These data highlight the dynamic nature of xenograft models and emphasize the importance of maintaining passage consistency throughout experiments.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Raise standards for preclinical cancer research
Begley, C. G., & Ellis, L. M. (2012) · Nature · doi:10.1038/483531a · Cited by 2,979 · cited 1×
“GO:0005201 extracellular matrix structural constituent 3 experimental data since the methods for generating test tumors can impact the study profoundly [38].”
BackgroundKruse, J.-P., & Gu, W. (2009) · Cell · doi:10.1016/j.cell.2009.04.050 · Cited by 1,610 · cited 1×
“This tumor suppressor and master regulator of the cell cycle is frequently mutated or deleted in tumors [17,18].”
BackgroundHarbig, J. (2005) · Nucleic Acids Research · doi:10.1093/nar/gni027 · Cited by 141
Translational approaches targeting the p53 pathway for anti‐cancer therapy
Essmann, F., & Schulze‐Osthoff, K. (2012) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01570.x · Cited by 77 · cited 1×
“, the Wee1 inhibitor MK-1775 or mutant p53 oncolytic adenovirus [19,20].”
Background
Cited by
Patient-derived xenografts undergo mouse-specific tumor evolution
Ben-David, U., Ha, G., Tseng, Y.-Y., Greenwald, N. F., Oh, C., Shih, J., McFarland, J. M., Wong, B., Boehm, J. S., Beroukhim, R., et al. (2017) · Nature Genetics · doi:10.1038/ng.3967 · Cited by 716
Stromal contribution to the colorectal cancer transcriptome
Isella, C., Terrasi, A., Bellomo, S. E., Petti, C., Galatola, G., Muratore, A., Mellano, A., Senetta, R., Cassenti, A., Sonetto, C., et al. (2015) · Nature Genetics · doi:10.1038/ng.3224 · Cited by 640
Proteome Discoverer—A Community Enhanced Data Processing Suite for Protein Informatics
Orsburn, B. C. (2021) · Proteomes · doi:10.3390/proteomes9010015 · Cited by 336
Self-citationRabben, H.-L., Andersen, G. T., Ianevski, A., Olsen, M. K., Kainov, D., Grønbech, J. E., Wang, T. C., Chen, D., & Zhao, C.-M. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.625991 · Cited by 24
Metadata
- Authors
- Hollingshead, M. G., Stockwin, L. H., Alcoser, S. Y., Newton, D. L., Orsburn, B. C., Bonomi, C. A., Borgel, S. D., Divelbiss, R., Dougherty, K. M., Hager, E. J., Holbeck, S. L., Kaur, G., Kimmel, D. J., Kunkel, M. W., Millione, A., Mullendore, M. E., Stotler, H., & Collins, J.
- Venue
- BMC Genomics
- Published
- 2014
- Volume
- 15
- Issue
- 1
- Pages
- 393
- ISSN
- 1471-2164 (ISSN-L)
- OpenAlex
- W2012277838
- Cited by
- 40
- References
- 4
- FWCI
- 1.58
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Gene expression profiling of 49 human tumor xenografts from in vitro culture through multiple in vivo passages - strategies for data mining in support of therapeutic studies. https://app.cochat.ai/papers/10.1186/1471-2164-15-393
- The paper
- Hollingshead, M. G., Stockwin, L. H., Alcoser, S. Y., Newton, D. L., Orsburn, B. C., Bonomi, C. A., Borgel, S. D., Divelbiss, R., Dougherty, K. M., Hager, E. J., Holbeck, S. L., Kaur, G., Kimmel, D. J., Kunkel, M. W., Millione, A., Mullendore, M. E., Stotler, H., & Collins, J. (2014). Gene expression profiling of 49 human tumor xenografts from in vitro culture through multiple in vivo passages - strategies for data mining in support of therapeutic studies. BMC Genomics. https://doi.org/10.1186/1471-2164-15-393
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.